查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553615

甲状腺疾病治疗的市场规模、份额和趋势分析报告：按适应症、药物、分销管道、给药途径、地区和细分市场预测，2024-2030年

Thyroid Gland Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypothyroidism), By Drug (Levothyroxine), By Distribution Channel, By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

甲状腺疾病治疗市场的成长与趋势：

预计2030年全球甲状腺疾病治疗市场规模将达28.4亿美元，2024年至2030年复合年增长率预计为3.6%。

由于全球甲状腺疾病的盛行率不断上升，预计未来几年抗甲状腺药物的需求将会增加。甲状腺机能低下症是美国住院的主要原因之一，医疗保健专业人员和患者对疾病管理意识的提高也是推动市场成长的因素之一。有各种私人和公共组织致力于传播疾病管理意识，包括英国甲状腺基金会、美国甲状腺协会 (ATA) 和加拿大甲状腺基金会。

对这些药物的需求不断增加，导致了各种治疗甲状腺疾病的学名药药物的仿製药的开发。学名药製造商正在专注于获得竞争优势的策略，包括新产品开发、加强分销管道、地理扩张以及与其他公司的产品合作。此外，核准品牌药学名药药的监管机构努力克服产品核可延迟的问题，并以更低的价格提供这些药物。预计这将在预测期内提振市场。

甲状腺疾病治疗市场报告亮点

  • 甲状腺机能低下症在市场上占据主导地位，到 2023 年将占 68.7%的市场占有率，预计在整个预测期内将保持其地位。另一方面，由于格雷夫兹病的盛行率不断增加，预计甲状腺功能亢进将稳定增长。
  • 口服给药是最优选或最常用的给药途径，因为其方便且简单有助于提高病患的依从性。这个市场是由强大的口服抗甲状腺药物产品线推动的。
  • 由于门诊处方药支出随着整体医疗保健支出的增加而增加，批发分销在 2023 年占据最大的市场收益占有率，达到 46.7%。预计电子商务将在未来几年内出现利润丰厚的成长。
  • 亚洲国家，尤其是印度和中国，预计未来几年将显着成长。
  • 市场分散，製药公司规模各异。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章甲状腺疾病治疗市场的变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 甲状腺疾病治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章 甲状腺疾病治疗市场：按适应症估计与趋势分析

  • 细分仪表板
  • 甲状腺疾病治疗市场：2023年及2030年适应症变化分析
  • 甲状腺机能低下症
  • 甲状腺功能亢进症

第五章甲状腺疾病治疗市场：按药物估计和趋势分析

  • 细分仪表板
  • 甲状腺疾病治疗市场：2023年及2030年药物波动分析
  • 左旋甲状腺素
  • 碘甲状腺素
  • 丙硫氧嘧啶
  • 咪唑类化合物
  • 其他的

第六章甲状腺疾病治疗市场：依通路估算与趋势分析

  • 细分仪表板
  • 甲状腺疾病治疗市场：2023年及2030年通路变化分析
  • 批发销售
  • 零售
  • 网路药房

第七章甲状腺疾病治疗市场：依途径估计与趋势分析

  • 细分仪表板
  • 甲状腺疾病治疗市场：2023 年和 2030 年按给药途径的变化分析
  • 口服
  • 静脉

第八章甲状腺疾病治疗市场：区域估计与趋势分析

  • 2023 年和 2030 年按地区分類的甲状腺疾病治疗市场占有率
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Abbvie Inc.
    • Amgen Inc.
    • GSK Plc
    • Merck KGaA
    • Viatris Inc.
    • Novartis AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Elexis Inc.
    • IBSA Pharma（IBSA Group）
简介目录
Product Code: GVR-2-68038-118-4

Thyroid Gland Disorder Treatment Market Growth & Trends:

The global thyroid gland disorder treatment market size is expected to reach USD 2.84 billion in 2030 and is projected to grow at a CAGR of 3.6% from 2024 to 2030. An increase in the prevalence of thyroid diseases around the globe is expected to drive demand for anti-thyroid drugs in the coming years. Hypothyroidism is one of the leading causes of hospitalization in U.S. Growing awareness about disease management amongst healthcare professionals and patients is another factor augmenting the market growth. There are various private and public organizations working toward spreading awareness related to disease management, such as the British Thyroid Foundation, The American Thyroid Association (ATA), and Thyroid Foundation of Canada.

Rising demand for these drugs has resulted in the development of various generic equivalents of branded drugs to treat thyroid gland disorders. Generic drug manufacturers are focusing on strategies such as new product development, distribution channel enhancement, regional expansions, and collaborations with other companies for marketing their products to gain an edge over the competition. In addition, regulatory authorities that approve generic versions of branded drugs are working to overcome delays in product approvals and enable the availability of these drugs at a lower price. This is expected to boost the market over the forecast period.

Thyroid Gland Disorder Treatment Market Report Highlights:

  • Hypothyroidism dominated the market and accounted for a market share of 68.7% in 2023 and is expected to maintain its position throughout the forecast period. On the other hand, hyperthyroidism is expected to witness steady growth on account of the increase in the incidence of Graves' disease
  • The oral route is the most preferred or most frequently used route of administration owing to its convenience and simplicity, which helps improve patient compliance. The market is driven by the presence of a strong pipeline of oral anti-thyroid medications
  • Wholesale distribution accounted for the largest market revenue share of 46.7% in 2023 owing to increasing spending on outpatient prescription drugs along with overall healthcare expenditure. E-commerce is expected to witness lucrative growth in the coming years
  • Asian countries, especially India and China, are expected to observe remarkable growth in the coming years
  • The market is fragmented in nature, with the presence of various large and small pharmaceutical players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Thyroid Gland Disorder Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Thyroid Gland Disorder Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Thyroid Gland Disorder Treatment Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Thyroid Gland Disorder Treatment Market: Indication Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Hypothyroidism
    • 4.3.1. Hypothyroidism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Hyperthyroidism
    • 4.4.1. Hyperthyroidism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Thyroid Gland Disorder Treatment Market: Drug Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Thyroid Gland Disorder Treatment Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Levothyroxine
    • 5.3.1. Levothyroxine Thyroid Gland Disorder Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Liothyroxine
    • 5.4.1. Liothyroxine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Propylthiouracil
    • 5.5.1. Liothyroxine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Imidazole-based compounds
    • 5.6.1. Imidazole-based compounds Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Thyroid Gland Disorder Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Thyroid Gland Disorder Treatment Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Wholesale Distribution
    • 6.3.1. Wholesale Distribution Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Sales
    • 6.4.1. Retail Sales Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Thyroid Gland Disorder Treatment Market: Route of Administration Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Thyroid Gland Disorder Treatment Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Oral
    • 7.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Intravenous
    • 7.4.1. Intravenous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Thyroid Gland Disorder Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Thyroid Gland Disorder Treatment Market Share, By Region, 2023 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Sweden Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Abbvie Inc.
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Amgen Inc.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. GSK Plc
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Merck KGaA
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Viatris Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Novartis AG
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Pfizer Inc.
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Takeda Pharmaceutical Company Limited
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Elexis Inc.
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. IBSA Pharma (IBSA Group)
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives